Admedus is developing a range of immunotherapies based on Professor Ian Frazer's next-generation DNA vaccine technology.
Working with immunologist Professor Ian Frazer, the creator of the world’s first prophylactic cervical cancer vaccine Gardasil®, Admedus is developing therapeutic vaccines for the treatment and prevention of infectious diseases and cancers.
Admedus has two key programs targeting Herpes Simplex Virus 2 (HSV-2) and Human Papillomavirus (HPV). The Admedus HSV-2 therapeutic vaccine is in a Phase II clinical trial and has achieved successful results to date. The HPV therapeutic vaccine is on track to enter a Phase Ib clinical trial in 2016, following the expected successful completion of pre-clinical studies.
Professor Frazer and his team at the Translational Research Institute use a unique optimisation technology designed to improve immune responses to DNA vaccines. The patented codon optimisation DNA technology enhances protein expression in the cell or tissue targeted and results in an improved humoral response. The second component of the technology, also patent protected, is to use a mixture of DNAs encoding ubiquitinated and non ubiquitinated proteins. This strategy enhances the degradation of the protein and optimises T cell responses, while preserving structural epitopes necessary for B cells responses, resulting in vaccines with prophylactic and therapeutic potential.
How immunotherapy & DNA vaccines work
DNA vaccine technology is used to stimulate humoral (antibody) and/or cellular (T-cell) immune responses that have an enhanced ability to destroy infected or cancerous cells.